About the Event
In this installment of Psychiatry and Behavioral Sciences Grand Rounds, Jeffrey R. Strawn, M.D., presents “Pediatric Anxiety Disorders: Using Neurobiology to Bridge the Gap From Risk to Remission.” Strawn is a professor of psychiatry, pediatrics and clinical pharmacology at the University of Cincinnati’s College of Medicine.
For more information about the event, email Jennifer Braham.
Upon request, Dell Medical School will provide interpretation services at this event. Please notify Jennifer by March 3, 2024, if interpretation is needed.
By the end of this presentation, the audience participant should be able to:
- Describe the risk factors and developmental epidemiology of anxiety disorders in youth.
- Explore the evidence of efficacy for various medications in the treatment of pediatric anxiety.
- Discuss side effect risks associated with antidepressant medications for pediatric anxiety.
- Describe how co-morbid conditions affect treatment response in pediatric anxiety disorders.
- Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
- Secondary: Other health care professionals
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice.
- IOM: Provide patient-centered; Work in interdisciplinary teams; Employ evidenced-based practice; Apply quality improvement; Utilize informatics
- IECC: Interprofessional Teamwork & Team-based Practice; Interprofessional Communication; Values & Ethics for Interprofessional Practice
Jeffrey R. Strawn, M.D., speaker for this educational activity, has received grants/research support from NIH, PCORI, Abbvie and Myriad. He serves as a consultant for Otsuka and Cerevel. He is on the speaker’s bureau for Neuroscience Education Institute. He receives royalties from Springer, UpToDate and Cambridge University Publishing.
Mark H. Townsend, M.D., M.S.; Carol L. Alter, M.D.; Lloyd S. Berg, Ph.D., ABPP; Octavio N. Martinez Jr., M.D., MPH; Barbara Springer; and Jennifer Braham, M.S., planners for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
Jeffrey Newport, M.D., M.S., MDiv, planner for this educational activity, received grants/research support from Navitor Pharmaceuticals and Sage Therapeutics, and he is a consultant for Sage Therapeutics. He received an honorarium for serving on the advisory board of Sage Therapeutics, Merck and Janssen.
Charles B. Nemeroff, M.D., Ph.D., planner for this educational activity, is a consultant for ANeuroTech (division of Anima BV), Signant Health, Janssen Research & Development LLC, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Clexio Bioscience LTD, EcoR1 Capital LLC, EmbarkNeuro (formerly AncoraBio), Galen Mental Health LLC, Goodcap Pharmaceuticals Inc., ITI Inc., LUCY Scientific Discovery, Relmada Therapeutics Inc., Sage Therapeutics, Senseye Inc., and Precisement Health. He is a stock shareholder (directly purchased) of Xhale, Seattle Genetics, Antares, BI Gen Holdings Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Precisement Health, and Relmada Therapeutics Inc. Nemeroff is on the scientific advisory boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR) Inc., Galen Mental Health, LLC, Heading Health, LLC, Pasithea Therapeutics Corp, Sage Therapeutics, Inc and Senseye, Inc. He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
The CME Advisory Committee, reviewers of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this live course for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.